{
    "organizations": [],
    "uuid": "f9de57978202d82c415f00c0c4f8adecf1bc8b3c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-spring-bank-pharmaceuticals-says-n/brief-spring-bank-pharmaceuticals-says-net-loss-for-three-months-ended-march-31-2018-was-4-9-mln-or-0-37-per-share-idUSFWN1S41BT",
    "ord_in_thread": 0,
    "title": "BRIEF-Spring Bank Pharmaceuticals Says Net Loss For Three Months Ended March 31, 2018 Was $4.9 Mln, Or $0.37 Per Share",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News April 27, 2018 / 1:12 PM / Updated 9 minutes ago BRIEF-Spring Bank Pharmaceuticals Says Net Loss For Three Months Ended March 31, 2018 Was $4.9 Mln, Or $0.37 Per Share Reuters Staff 1 Min Read\n Spring Bank Pharmaceuticals Inc :\n* SPRING BANK PHARMACEUTICALS INC - NET LOSS FOR THREE MONTHS ENDED MARCH 31, 2018 WAS $4.9 MILLION, OR $0.37 PER SHARE\n* SPRING BANK PHARMACEUTICALS - ANTICIPATES THAT EXISTING CASH, CASH EQUIVALENTS WILL ENABLE CO TO FUND OPERATING EXPENSES & CAPEX REQUIREMENTS INTO Q4 2019\n* SPRING BANK PHARMA - ANTICIPATES THAT EXISTING CASH, CASH EQUIVALENTS WILL NOT BE SUFFICIENT TO FUND INITIATION OF ANY PHASE 3 TRIAL FOR INARIGIVIR Source text for Eikon: ",
    "published": "2018-04-27T21:12:00.000+03:00",
    "crawled": "2018-04-27T16:30:33.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "bank",
        "pharmaceutical",
        "say",
        "net",
        "loss",
        "three",
        "month",
        "ended",
        "march",
        "mln",
        "per",
        "share",
        "reuters",
        "staff",
        "min",
        "read",
        "spring",
        "bank",
        "pharmaceutical",
        "inc",
        "spring",
        "bank",
        "pharmaceutical",
        "inc",
        "net",
        "loss",
        "three",
        "month",
        "ended",
        "march",
        "million",
        "per",
        "share",
        "spring",
        "bank",
        "pharmaceutical",
        "anticipates",
        "existing",
        "cash",
        "cash",
        "equivalent",
        "enable",
        "co",
        "fund",
        "operating",
        "expense",
        "capex",
        "requirement",
        "q4",
        "spring",
        "bank",
        "pharma",
        "anticipates",
        "existing",
        "cash",
        "cash",
        "equivalent",
        "sufficient",
        "fund",
        "initiation",
        "phase",
        "trial",
        "inarigivir",
        "source",
        "text",
        "eikon"
    ]
}